GlassScriptPhysician profile
Tracy Banghart
NPI 1689332041
$5,282.00
in general payments reported to CMS, 2019-2025
21 companies · $1,256 in 2025
The $1,256 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.23 · 2022: $1,064 · 2023: $1,061 · 2024: $1,884 · 2025: $1,256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,200.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,276.86 | 2022-2025 | |
| Janssen Biotech, INC. | $784.93 | 2022-2025 | Tremfya, Stelara, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $707.25 | 2022-2024 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $276.14 | 2021-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $196.07 | 2024-2025 | Voquezna |
| Vivus LLC | $186.55 | 2022-2025 | Pancreaze |
| Regeneron Healthcare Solutions, INC. | $168.98 | 2022-2024 | Dupixent |
| Genzyme Corporation | $117.33 | 2023-2025 | |
| Gilead Sciences, INC. | $96.12 | 2022-2024 | Epclusa |
| Celgene Corporation | $91.60 | 2022-2024 | Zeposia |
| Ipsen Biopharmaceuticals, INC | $81.25 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $74.30 | 2024 | |
| Pfizer INC. | $55.99 | 2022-2024 | |
| Stryker Corporation | $29.13 | 2024 | Triathlon |
| Jazz Pharmaceuticals INC. | $28.22 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $27.05 | 2022-2023 | Sutab |
| Ardelyx, INC. | $23.47 | 2023 | Ibsrela |
| Baxter Healthcare | $16.90 | 2024 | Hillrom - Vest System Model 105 Home Care |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.85 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.60 | 2023 | Ofev |
| Intercept Pharmaceuticals, INC. | $14.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Banghart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.